Dr. Reddy’s Laboratories Ltd on Wednesday announced the launch of Hevaxin, a novel recombinant vaccine for the prevention of Hepatitis E virus infection
in India.
The vaccine is the only one approved by the Drug Controller General of India for active immunisation against Hepatitis E in adults aged 18 to 65 years. Clinical studies have shown that Hevaxin provides protection with long-lasting immunity and a favourable safety and tolerability profile.
Hepatitis E remains a major health concern, particularly in India, where it accounts for a significant share of acute hepatitis and acute liver failure cases.
According to the World Health Organization, the virus infects nearly 20 million people globally every year, with high mortality risks among vulnerable groups such as women of childbearing age, patients with chronic liver disease and those with weakened immunity.
Dr. Reddy’s said the launch supports India’s National Viral Hepatitis Control Programme and addresses a critical unmet need in preventive healthcare. The company has partnered with Shenzhen Mellow Hope Pharm and Urihk Pharmaceutical for the marketing and distribution of Hevaxin in India.
As of 03:12 PM, shares of Dr Reddy’s Laboratories Ltd were trading at ₹1,245.20, down 0.88% on the NSE.
